Your browser doesn't support javascript.
loading
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications.
Merola, Aristide; Romagnolo, Alberto; Dwivedi, Alok K; Padovani, Alessandro; Berg, Daniela; Garcia-Ruiz, Pedro J; Fabbri, Margherita; Artusi, Carlo Alberto; Zibetti, Maurizio; Lopiano, Leonardo; Pilotto, Andrea; Bonacina, Sonia; Morgante, Francesca; Zeuner, Kirsten; Griewing, Christopher; Schaeffer, Eva; Rodriguez-Porcel, Federico; Kauffman, Marcelo; Turcano, Pierpaolo; de Oliveira, Lais M; Palermo, Giovanni; Shanks, Emily; Del Sorbo, Francesca; Bonvegna, Salvatore; Savica, Rodolfo; Munhoz, Renato P; Ceravolo, Roberto; Cilia, Roberto; Espay, Alberto J.
Afiliação
  • Merola A; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Aristide.Merola@osumc.edu.
  • Romagnolo A; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Dwivedi AK; Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
  • Padovani A; Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
  • Berg D; Department of Neurology, Christian-Albrecht-University Kiel, Kiel, Germany.
  • Garcia-Ruiz PJ; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Fabbri M; Department of Neurology, Movement Disorders Unit, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.
  • Artusi CA; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Zibetti M; Laboratory of Pharmacology and Therapeutics, Facultade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Lopiano L; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Pilotto A; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Bonacina S; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Morgante F; Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
  • Zeuner K; Parkinson's Disease Rehabilitation Centre, FERB ONLUS-S. Isidoro Hospital, Trescore Balneario, BG, Italy.
  • Griewing C; Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
  • Schaeffer E; Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
  • Rodriguez-Porcel F; Dipartimento Di Medicina Clinica E Sperimentale, Università Di Messina, Messina, Italy.
  • Kauffman M; Department of Neurology, Christian-Albrecht-University Kiel, Kiel, Germany.
  • Turcano P; Department of Neurology, Christian-Albrecht-University Kiel, Kiel, Germany.
  • de Oliveira LM; Department of Neurology, Christian-Albrecht-University Kiel, Kiel, Germany.
  • Palermo G; Department of Neurology, Medical University of South Carolina, Charleston, SC, USA.
  • Shanks E; Consultorio Y Laboratorio de Neurogenética, Facultad de Medicina, Centro Universitario de Neurologia "José María Ramos Mejía" Y Division Neurologia, Hospital J.M.Ramos Mejia, UBA, Buenos Aires, Argentina.
  • Del Sorbo F; Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
  • Bonvegna S; Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
  • Savica R; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Munhoz RP; Department of Neurology, Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
  • Ceravolo R; Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy.
  • Cilia R; Fondazione IRCCS Istituto Neurologico Carlo Besta, Movement Disorders Unit, Milan, Italy.
  • Espay AJ; Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.
J Neurol ; 267(10): 2949-2960, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32488298
ABSTRACT

OBJECTIVE:

We sought to evaluate demographic, clinical, and habits/occupational variables between phenotypic extremes in Parkinson's disease (PD).

METHODS:

Databases from nine movement disorders centers across seven countries were retrospectively searched for subjects meeting criteria for very slowly progressive, benign, PD (bPD) and rapidly progressive, malignant, PD (mPD). bPD was defined as Hoehn and Yahr (H&Y) stage ≤ 3, normal cognitive function, and Schwab and England (S&E) score ≥ 70 after ≥ 20 years of PD (≥ 10 years if older than 60 at PD onset); mPD as H&Y > 3, S&E score < 70, and cognitive impairment within 10 years from PD onset. We performed between-group analysis of demographic, habits/occupational, and clinical features at baseline and follow-up and unsupervised data-driven analysis of the clinical homogeneity of bPD and mPD.

RESULTS:

At onset, bPD subjects (n = 210) were younger, had a single limb affected, lower severity and greater asymmetry of symptoms, and lower prevalence of depression than mPD (n = 155). bPD was associated with active smoking and physical activity, mPD with agricultural occupation. At follow-up, mPD showed higher prevalence of depression, hallucinations, dysautonomia, and REM behaviour disorder. Interestingly, the odds of mPD were significantly reduced by the presence of dyskinesia and wearing-off. Data-driven analysis confirmed the independent clustering of bPD and mPD, with age at onset emerging as a critical discriminant between the two groups (< 46-year-old vs. > 68-year-old).

CONCLUSIONS:

Phenotypic PD extremes showed distinct demographic, clinical, and habits/occupational factors. Motor complications may be conceived as markers of therapeutic success given their attenuating effects on the odds of mPD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtorno do Comportamento do Sono REM Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtorno do Comportamento do Sono REM Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article